Last reviewed · How we verify
amoxicillin or moxifloxacin
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Uncomplicated urinary tract infections, Acute bacterial otitis media, Community-acquired pneumonia.
At a glance
| Generic name | amoxicillin or moxifloxacin |
|---|---|
| Sponsor | Centre Hospitalier Universitaire de Nice |
| Drug class | Penicillin antibiotic |
| Target | Penicillin-binding proteins |
| Modality | Small molecule |
| Therapeutic area | Infectious diseases |
| Phase | Phase 3 |
Mechanism of action
This results in the disruption of the bacterial cell wall, ultimately leading to cell lysis and death. Amoxicillin is a broad-spectrum antibiotic, effective against a wide range of Gram-positive and Gram-negative bacteria.
Approved indications
- Uncomplicated urinary tract infections
- Acute bacterial otitis media
- Community-acquired pneumonia
Common side effects
- Diarrhea
- Nausea
- Vomiting
Key clinical trials
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis (PHASE4)
- A Platform Trial for Gram Negative Bloodstream Infections (NA)
- Clarithromycin Treatment to Prevent Sepsis Progression in CAP (REACT) (PHASE3)
- Comparing Oral Versus Parenteral Antimicrobial Therapy (PHASE4)
- Ampicillin and Ceftriaxone for the Treatment of Enterococcus Faecalis Infective Endocarditis. (PHASE4)
- A Study of Fluoroquinolones Exposure and Collagen-Related Serious Adverse Events
- BALANCE+ Vanguard Phase (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- amoxicillin or moxifloxacin CI brief — competitive landscape report
- amoxicillin or moxifloxacin updates RSS · CI watch RSS
- Centre Hospitalier Universitaire de Nice portfolio CI